Comparative Pharmacology
Head-to-head clinical analysis: IOFLUPANE I 123 versus PYLARIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOFLUPANE I 123 versus PYLARIFY.
IOFLUPANE I-123 vs PYLARIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ioflupane I-123 is a radiopharmaceutical that binds with high affinity to the dopamine transporter (DAT) in the striatum. It allows visualization of presynaptic dopaminergic neurons via single-photon emission computed tomography (SPECT) imaging.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
Intravenous: 148-185 MBq (4-5 mCi) administered as a single IV bolus injection over 20-30 seconds, followed by saline flush.
1 mg/kg IV bolus administered once.
None Documented
None Documented
Clinical Note
moderateIoflupane I-123 + Methylphenidate
"Ioflupane I-123 may decrease effectiveness of Methylphenidate as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Venlafaxine
"Ioflupane I-123 may decrease effectiveness of Venlafaxine as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Nefazodone
"Ioflupane I-123 may decrease effectiveness of Nefazodone as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Fluvoxamine
Terminal elimination half-life of ioflupane I-123 is approximately 25-30 hours. This prolonged half-life allows for imaging up to 6-8 hours post-injection with sustained target-to-background ratio, but requires consideration for radiation safety.
Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice.
Primarily renal; about 60% of administered radioactivity excreted in urine within 24 hours, with 38% as unchanged ioflupane and 22% as metabolites. Fecal excretion accounts for approximately 14% over 48 hours. Additional elimination via biliary route is minimal.
Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical
"Ioflupane I-123 may decrease effectiveness of Fluvoxamine as a diagnostic agent."